Depression

Looking to stay up to date on MDD research? This research collection reviews outcomes on metabolic abnormalities, biomarkers, and more.

Presenters at the 2023 APA Annual Meeting compared definitions of treatment-resistant depression.

Check out this review of the 2023 APA Annual Meeting presentation on the efficacy and safety of repeat treatment courses using novel medicine, zuranolone.

An inside look at what treatments are being discussed in San Francisco...

Does treatment-resistant depression exist? These 2023 APA Annual Meeting panelists discuss definitions in this exclusive video.

Study results presented at the 2023 American Psychiatric Association Annual Meeting.

A look at the theme for the 2023 American Psychiatric Association Annual Meeting.

Don't miss this session at the APA 2023 Annual Meeting in San Francisco!

Study investigates connections between rTMS and factors including depression and cognitive performance.

Ketamine is relatively new to the average American. What can you share with them as a mental health clinician?

When considering transcranial magnetic stimulation as a treatment option for treatment-resistant depression, here are some key questions to ask the patient.

Test your knowledge on issues in major depressive disorder.

When the Surgeon General notices the loneliness problem, it is definitely a mayday moment.

“Our hope for patients suffering from TRD is that their serious, but often treatable condition is recognized earlier in the treatment paradigm, and they are put on a treatment that works best for their specific type of depression.”

From to co-occurring substance use and eating disorders to treatment options for OCD, here are highlights from the week in Psychiatric Times.

A psychiatrist and their patient reflect on treatment.

What is the current role of lithium?

From gut microbiota and SSRIs in MDD to nonpharmacological interventions following TBI, here are highlights from the week in Psychiatric Times.

The experts weighed in on a wide variety of psychiatric issues for the March 2023 issue of Psychiatric Times.

A gut feeling? Researchers analyzed the gut microbiome in major depression disorder and its modulation by SSRI antidepressants.

New results for a study evaluating lumateperone.

From an update on at-home ketamine therapy to the psychopharmacologic treatment of bipolar depression, here are highlights from the week in Psychiatric Times.

What is the best evidence-based medication treatment for acute bipolar II depression?

Study results show that the therapy activates serotonin (5-HT) and improves stress-coping ability.

The Future of Mental Health: Ketamine Therapy Report revealed that 55% of Americans who tried at home ketamine took more than the recommended dose.